EGFR and neoplasm: Drug resistance to treatment with TKIs also develops naturally and can be divided into on-target mutations (EGFR-T790M to first/second generation EGFR-TKIs), off-target mutations (overexpression of HGF, EGFR-independent resistant mechanisms), and histological transformation to a different tumor type (neuroendocrine or mesenchymal).